PTC Therapeutics ALS drug fails to meet endpoints as trials shut down
The announcement means the company will be pulling the plug on the CardinALS trial after its amyotrophic lateral sclerosis drug failed to halt disease progression.
PTC axes utreloxastat program after phase 2 ALS failure
But utreloxastat had little effect on ALS in the phase 2 trial. PTC powered the study to show whether twice-daily oral dosing of utreloxastat could achieve a two-point difference on ALSFRS, an instrument for evaluating the functional status of ALS patients. The drug candidate fell short of that bar.
PTC Scraps ALS Asset Utreloxastat After Mid-Stage Fail, Analysts Look to PKU Opportunity
Despite the “unfortunate” failure, William Blair analysts do not believe that the utreloxastat readout will heavily affect PTC, instead postulating that the upcoming FDA decision on its phenylketonuria candidate sepiapterin will be a stronger driver of the biotech’s stock.
PTC Therapeutics: Phase 2 CardinALS study did not meet its primary endpoint
PTC Therapeutics (PTCT) announced that the global Phase 2 placebo-controlled CardinALS study did not meet its primary endpoint of slowing
PTC's utreloxastat fails Phase 2 clinical study for ALS
PTC Therapeutics (NASDAQ:PTCT) said a Phase 2 placebo-controlled study of its ALS drug candidate utreloxastat failed to meet its primary and secondary efficacy endpoints. The biotech company said the drug failed to demonstrate statistical significance in the slowing of disease progression,
Inspiring Ogden High football coach Erik Thompson calling it a career — and what a career it was
Thompson, who has spent the latter part of his coaching career while suffering from ALS, is much more than a fine football ...
He runs Upstate NY’s first Chick-fil-A without moving or speaking a word: ‘I’m still climbing’
Since Jimmer Szatkowski opened Upstate New York’s first Chick-fil-A in 2018, he’s been at the restaurant most every day. He’s ...
An artist with ALS creates beautiful portraits of people with the fatal disease
ALS is a progressive neurodegenerative disease — and there is no cure. Brunner, who was running 3 miles a day at the onset of ...
pharmaphorum2h
Neuralink unveils trial linking brain implant to robotic arm
In a post on X.com, Neuralink said it had been granted regulatory approval for "a new feasibility trial to extend BCI control ...
Live Science on MSN2d
'Exercise juice' released by muscles helps nerves grow, study finds
In a new study of mouse cells, scientists found that both the biochemical and mechanical effects of exercise may help injured ...
FierceBiotech1d
PTC sells priority review voucher from Kebilidi approval for $150M
PTC Therapeutics may reeling from the failure of its amyotrophic lateral sclerosis (ALS) drug utreloxastat yesterday, but the ...
AI-Powered Communication Solution For People Living With ALS Revealed At Lenovo Tech World
Erin Taylor, a disability advocate and botany enthusiast with ALS, used the technology to introduce herself and then welcome ...
IIT-BHU developing med device with potential to cure sclerosis
A team from IIT-BHU is developing a revolutionary cell-based device using 3D bioprinting technology to potentially cure ...
Neuralink wants its brain chip to control a robot arm next
There are now at least two patients who have had Neuralink's brain chip implanted in their head. While there have been some ...
MaaT Pharma Announces Positive Phase 1b Results, Meeting Primary Endpoint in the Evaluation of MaaT033 in Amyotrophic Lateral Sclerosis (ALS)
MaaT Pharma Announces Positive Phase 1b Results, Meeting Primary Endpoint in the Evaluation of MaaT033 in Amyotrophic Lateral ...